Safety and efficacy of affinity-purified, anti-tumor necrosis factor-α, ovine fab for injection (CytoFab) in severe sepsis

Critical Care Medicine

Volumn 34, Issue 9, 2006, Pages 2271-2281

  Rice, Todd W ^a   Wheeler, Arthur P ^a   Morris, Peter E ^b   Paz, Harold L ^c   Russell, James A ^d   Edens, Tonya R ^a   Bernard, Gordon R ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cytokines; Phase II clinical trial; Polyclonal; Randomized controlled trial; Septic shock; Tumor necrosis factor

Indexed keywords

ALBUMIN; ANTIBODY; CYTOFAB; HUMAN ANTISHEEP ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; INTERLEUKIN 6; INTERLEUKIN 8; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY TITER; ARTICLE; ARTIFICIAL VENTILATION; CANADA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INTENSIVE CARE UNIT; LUNG LAVAGE; MALE; MORTALITY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; UNITED STATES; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIBODIES; BRONCHOALVEOLAR LAVAGE FLUID; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOLOGIC FACTORS; INFUSIONS, INTRAVENOUS; INTENSIVE CARE UNITS; INTERLEUKIN-6; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RESPIRATION, ARTIFICIAL; SEPSIS; SHEEP; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33747502519     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000230385.82679.34     Document Type: Article

References (45)

1. Martin GS, Mannino DM, Eaton S, et al: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348:1546-1554
2. Angus DC, Linde-Zwirble WT, Lidicker J, et al: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310
3. Bone RC, Balk RA, Cerra FB, et al: American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992; 101:1644-1655
4. Hesse DG, Tracey KJ, Fong Y, et al: Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet 1988; 166:147-153
5. Beutler BA, Milsark IW, Cerami A: Cachectin/tumor necrosis factor: Production, distribution, and metabolic fate. in vivo. J Immunol 1985; 135:3972-3977
6. van der Poll T, van Deventer SJH: Cytokines and anticytokines in the pathogenesis of sepsis. Infect Dis Clin North Am 1999; 13:413-426
7. Michie HR, Manogue KR, Spriggs DR, et al: Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 1988; 318:1481-1486
8. Tracey KJ, Cerami A: Tumor necrosis factor: An updated review of its biology. Crit Care Med 1993; 21:S415-S422
9. Schirmer JW, Schirmer JM, Fry DE: Recombinant human tumor necrosis factor produces hemodynamic changes characteristic of sepsis and endotoxemia. Arch Surg 1989; 124:445-448
10. Michie HR, Spriggs DR, Manogue KR, et al: Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. Surgery 1988; 104:280-286
11. Thijs LG, Hack CE: Time course of cytokine levels in sepsis. Intensive Care Med 1995; 21(Suppl 2):S258
12. van Deventer SJH, Buller HR, ten Cate JW, et al: Experimental endotoxemia in humans: Analysis of cytokine release and coagulation, fibrinolytic and complement pathways. Blood 1990; 76:2520-2526
13. Fong Y, Tracey KJ, Moldawer LL, et al: Antibodies to cachectin/TNF reduce interleukin-1-β and interleukin-6 appearance during lethal bacteremia. J Exp Med 1989; 170:1627-1633
14. van der Poll T, Buller HR, ten Cate HT: Activation of coagulation after administration of TNF to normal subjects. N Engl J Med 1990; 322:1622-1627
15. Knaus WA, Draper EA, Wagner DP, et al: APACHE II: A severity of disease classification system. Crit Care Med 1985; 13:818-829
16. Bernard GR: The Brussels score. Sepsis 1997; 1:43-44
17. Schoenfeld DA, Bernard GR, for the ARDS Network: Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome. Crit Care Med 2002; 30:1772-1777
18. Dupont WD, Plummer WD: Power and sample size calculations: A review and computer program. Controlled Clin Trials 1990; 11:116-128
19. Fekade D, Knox K, Hussein K, et al: Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumor necrosis factor α. N Engl J Med 1996; 335:311-315
20. Wallis RS, Broder MS, Wong JY, et al: Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38:1261-1265
21. Gogos CA, Drosou E, Bassaris HP, et al: Proversus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis 2000; 181:176-180
22. Debets JM, Kampmeijer R, van der Linden MP, et al: Plasma tumor necrosis factor and mortality in critically ill septic patients. Crit Care Med 1989; 17:489-494
23. Abraham E, Wunderink R, Silverman H, et al: for the TNF-α MAb Sepsis Study Group: Efficacy and safety of monoclonal antibody to human tumor necrosis factor α in patients with sepsis syndrome. JAMA 1995; 273:934-941
24. Cohen J, Carlet J: The INTERSEPT Study Group: INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor [alpha] in patients with sepsis. Crit Care Med 1996; 24:1431-1440
25. Abraham E, Anzueto A, Gutierrez G, et al: Double-blind randomized controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. Lancet 1998; 351:929-933
26. Fisher CJ Jr, Agosti JM, Opal SM, et al: Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein: The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996; 334:1697-1702
27. Abraham E, Glauser MP, Butler T, et al: p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. JAMA 1997; 277:1531-1538
28. Reinhart K, Menges T, Gardlund B, et al: Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES study. Crit Care Med 2001; 29:765-769
29. Panacek EA, Marshall JC, Albertson TE, et al: Efficacy and safety of the monoclonal antitumor necrosis factor antibody F(ab′)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 2004; 32:2173-2182
30. Damas P, Ledoux D, Nys M, et al: Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 1992; 215:356-362
31. Fugger R, Zadrobilek E, Gotzinger P, et al: Perioperative TNF alpha and IL-6 concentrations correlate with septic state, organ function, and APACHE II scores in intra-abdominal infection. Eur J Surg 1993; 159:525-529
32. Knaus WA, Harrell FE Jr., LaBrecque JF, et al: Use of predicted risk of mortality to evaluate the efficacy of anticytokine therapy in sepsis. The rhIL-Ira Phase III Sepsis Study Group. Crit Care Med 1996; 24:46-56
33. Eichacker PQ, Parent C, Kalil A, et al: Risk and the efficacy of anti-inflammatory agents: retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med 2002; 166:1197-1205
34. Nelson PN, Reynolds GM, Waldron EE, et al: Monoclonal antibodies. Mol Pathol 2000; 53:111-117
35. Smith TW, Lloyd BL, Spicer N, et al: Immunogenicity and kinetics of distribution and elimination of sheep digoxin-specific IgG and Fab fragments in the rabbit and baboon. Clin Exp Immunol 1979; 36:384-396
36. Haitsma JJ, Uhlig S, Goggel R, et al: Ventilator-induced lung injury leads to loss of alveolar and systemic compartmentalization of tumor necrosis factor-α. Intensive Care Med 2000; 26:1515-1522
37. Molina PE, Bagby GJ, Stahls P: Hemorrhage alters neuroendocrine, hemodynamic, and compartment-specific TNF responses to LPS. Shock 2001; 16:459-465
38. Covell DG, Barbet J, Holton OD, et al: Pharmacokinetics of monoclonal immunoglobulin G1, F(ab′)2, and Fab′ in mice. Cancer Res 1986; 46:3969-3978
39. Schaumann W, Kaufmann B, Neubert P, et al: Kinetics of the Fab fragments of digoxin antibodies and of bound digoxin in patients with severe digoxin intoxication. Eur J Clin Pharmacol 1986; 30:527-533
40. Park WY, Goodman RB, Steinberg KP, et al: Cytokine balance in the lungs of patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 2001; 164:1896-1903
41. Kiehl MG, Ostermann H, Thomas M, et al: Inflammatory mediators in bronchoalveolar lavage fluid and plasma in leukocytopenic patients with septic shock-induced acute respiratory distress syndrome. Crit Care Med 1998; 26:1194-1199
42. Pacht ER, DeMichele SJ, Nelson JL, et al: Enteral nutrition with eicosapentaenoic acid, γ-linolenic acid, and antioxidants reduces alveolar inflammatory mediators and protein influx in patients with acute respiratory distress syndrome. Crit Care Med 2003; 31:491-500
43. Hyers TM, Tricomi SM, Dettenmeier PA, et al: Tumor necrosis factor levels in serum and bronchoalveolar lavage fluid of patients with adult respiratory distress syndrome. Am Rev Respir Dis 1991; 144:268-271
44. Bernard GR, Wheeler AP, Naum CC, et al: A placebo controlled, randomized trial of IL-10 in acute lung injury. Chest 1999; 116:260S
45. Goodman RB, Strieter RM, Martin DP, et al: Inflammatory cytokines in patients with persistence of the acute respiratory distress syndrome. Am J Respir Crit Care Med 1996; 154:602-611